Emmanuelle Liaudet-Coopman

ORCID#: https://orcid.org/0000-0001-9313-9690 Researcher ID#:http://www.researcherid.com/rid/N-4744-2017 Desroys du Roure P, Lajoie L, Gros L, Mallavialle A, Alcaraz LB, Mansouri H, Fenou L, Garambois V, David T, Coenon L, Boissière-Michot F, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, S Guiu, Chardès T, & Liaudet-Coopman E. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for ImmunoTherapy 2024 Jan 30;12(1):e007135. doi: 10.1136/jitc-2023-007135. David T, Mallavialle A, Faget J, Alcaraz LB, Lapierre M, Desroys du Roure P, Laurent-Matha V, Mansouri H, Jarlier M, Martineau P, Roger P, Guiu S, Chardès T, Liaudet-Coopman E. Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer, Br J Pharmacol. 2023 Nov 29. doi: 10.1111/bph.16291. Alcaraz LB, Mallavialle A, Mollevi C, Boissière-Michot F, Mansouri H, Simony-Lafontaine J, Laurent-Matha V, Chardès T, Jacot W, Turtoi A, Roger P, Guiu S, Liaudet-Coopman E. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. 2023) Int J Cancer 152:1243-1258. doi: 10.1002/ijc.34345. Alcaraz LB, Mallavialle A, David T, Derocq D, Delolme D, Dieryckx C, Boissière-Michot F, Simony-Lafontaine J, Du Manoir S, Huesgen PF, Overall CM, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. 2021) Theranostics 11: 6173-6192. doi: 10.7150/thno.58254. eCollection 2021. Ashraf Y*, Mansouri H*, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, M Jarlier, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, Du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, and Liaudet-Coopman E. (Immunotherapy of triple-negative breast cancer with cathepsin-D-targeting antibodies. 2019) J ImmunoTherapy Cancer 7:29-46. doi: 10.1186/s40425-019-0498-z. Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebière B, Meurice G, Oréar C, Hollingsworth RE, Abrahamson M, Lalmanach G, Overall CM & Liaudet-Coopman E (Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. 2012) FASEB J 26: 5172. doi: 10.1096/fj.12-205229. Derocq D, Prebois C, Beaujouin M, Laurent-Matha V, Pattingre S, Smith G & Liaudet-Coopman E (Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1 regulated intramembrane proteolysis. 2012) Oncogene 31,3202. doi: 10.1038/onc.2011.501. Beaujouin M, Prébois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth R, Zhang H, Yao Z, Hyman B, Van der Geer P, Smith G & Liaudet-Coopman E (Pro-cathepsin D interacts with the extracellular domain of LRP1beta chain and promotes LRP1-dependent fibroblast outgrowth. 2010) J Cell Sci. 123,3336. doi: 10.1242/jcs.070938. Beaujouin M, Baghdiguian S, Glondu-Lassis M, Berchem G & Liaudet-Coopman E (Overexpression of both catalytically active and inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. 2006) Oncogene 25,1967-73. doi: 10.1038/sj.onc.1209221. Laurent-Matha V, Maruani-Herrmann S, Prebois C, Beaujouin M, Glondu M, Noel A, Alvarez-Gonzalez ML, Blacher S, Coopman P, Baghdiguian S, Gilles C, Loncarek J, Freiss G, Vignon F & Liaudet-Coopman E (Catalytically inactive human cathepsin D triggers fibroblast invasive growth. 2005) J. Cell. Biol. 168: 489-99. doi: 10.1083/jcb.200403078.